Freenome, a company that is leading the way in early cancer detection through blood tests, has named Rob Guigley as its new chief commercial officer. Guigley will be in charge of the company’s efforts to carry out its exclusive U.S. licensing and commercialization deal with Exact Sciences. This agreement will help make Freenome’s colorectal cancer blood test more accessible. In addition, he will manage the growth of the company’s commercial operations for its current and future tests.
Health Technology Insights: MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has ended, which was a key step in completing the transaction that was first announced on August 6, 2025. The U.S. Food and Drug Administration is currently looking at the Premarket Approval Application for the first version of the test, known as SimpleScreen CRC. Approval is expected in the second half of 2026.
“Ash we move into this new phase, we are focused on building up our commercial leadership to ensure our CRC test reaches as many people as possible, while quickly moving forward with our multi-cancer developments and collecting real-world data through commercial testing,” said Aaron Elliott, Ph.D., CEO of Freenome. “Rob Guigley has a proven track record of building and scaling commercial teams in the primary care field, and his experience will be very helpful as we prepare for future clinical impact.”
Health Technology Insights: Found Health Launches GLP-1 Microdosing Program for Early Metabolic Dysfunction
Guigley has over 20 years of experience leading commercial teams in diagnostics, digital health, and healthcare technology. He has worked at Delfi Diagnostics, Invitae, Ambry Genetics, and Omada Health. He will guide Freenome’s go-to-market strategy with healthcare systems, focusing on integrating the company’s tests into primary care routines and developing support services for caregivers. His expertise in digital products and real-world data fits well with Freenome’s partnership with Exact Sciences. This partnership gives the company access to various types of patient data, which will be used to improve AI and machine learning models for different cancers. Freenome plans to launch a laboratory-developed lung cancer screening test in the second half of 2026 and is continuing to develop more than ten other cancer tests based on its multi-cancer research.
“What attracted me to Freenome is the combination of solid science, clinical validation, and a strong platform protected by a growing data advantage, along with a clear vision for making early detection available to everyone,” Guigley said. “I am looking forward to working with Exact Sciences to speed up access to SimpleScreen CRC after FDA approval, and I’m excited to build Freenome’s commercial structure to bring our multi-cancer test range to the market.” Freenome’s multiomics discovery platform examines several biomarkers, including epigenomics, transcriptomics, metabolomics, and proteomics, to find early signs of disease in the blood. The company aims to create a flexible laboratory platform that can offer multiple personalized tests based on individuals’ health profiles and eligibility guidelines. The tests are being fine-tuned for high sensitivity and clinically acceptable specificity to meet the needs of high-risk, elevated-risk, and average-risk populations. The company is currently evaluating certain health systems for a SimpleScreen CRC early access program launching in January 2026. The first patient samples are expected to arrive at Freenome’s clinical laboratory that month. The laboratory received CLIA certification in October, confirming it meets federal quality standards for reliability and accuracy.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 28 October 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
